# Amir Onn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/amir-onn/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,185 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 39 |
| i10-index | 82 |
| Last Known Institution | Sheba Medical Center |
| OpenAlex ID | https://openalex.org/A5074185199 |
| ORCID iD | 0000-0002-6602-0405 |
| Works | 204 |

## Researcher papers

- [Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial](https://scholariq.org/papers/genomic-and-transcriptomic-profiling-expands-precision-cancer-medicine-the/)
- [Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications](https://scholariq.org/papers/angiogenesis-and-lung-cancer-prognostic-and-therapeutic-implications/)
- [BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors](https://scholariq.org/papers/braf-mutant-lung-cancer-programmed-death-ligand-1-expression-tumor-mutational/)
- [Weight loss and improvement of obesity-related illness in 500 U.S. patients following laparoscopic adjustable gastric banding procedure](https://scholariq.org/papers/weight-loss-and-improvement-of-obesity-related-illness-in-500-u-s-patients/)
- [Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.](https://scholariq.org/papers/development-of-an-orthotopic-model-to-study-the-biology-and-therapy-of-primary/)
- [Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis](https://scholariq.org/papers/vandetanib-zd6474-an-orally-available-receptor-tyrosine-kinase-inhibitor-that/)
- [Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-<b> <i>neu</i> </b> Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer](https://scholariq.org/papers/synchronous-overexpression-of-epidermal-growth-factor-receptor-and-her2-b-i-neu/)
- [Alternating Electric Fields (Tumor-Treating Fields Therapy) Can Improve Chemotherapy Treatment Efficacy in Non-Small Cell Lung Cancer Both In Vitro and In Vivo](https://scholariq.org/papers/alternating-electric-fields-tumor-treating-fields-therapy-can-improve/)
- [Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial](https://scholariq.org/papers/afatinib-beyond-progression-in-patients-with-non-small-cell-lung-cancer/)
- [Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer](https://scholariq.org/papers/exhaled-breath-analysis-for-monitoring-response-to-treatment-in-advanced-lung/)
- [Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer](https://scholariq.org/papers/transformation-to-small-cell-lung-cancer-as-a-mechanism-of-resistance-to/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Sheba Medical Center](https://scholariq.org/institutions/sheba-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.